Core Viewpoint - The stock price of Jianzhijia has experienced a decline of 10.20% year-to-date, with a recent drop of 2.03% on December 22, 2025, indicating potential challenges in the company's market performance [2][1]. Company Overview - Jianzhijia Pharmaceutical Chain Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on September 27, 2004. It was listed on December 1, 2020. The company specializes in the retail of health products, including pharmaceuticals, health foods, personal care items, and daily consumables [2]. - The revenue composition of Jianzhijia includes 72.60% from prescription and non-prescription drugs (with non-prescription drugs at 39.64% and prescription drugs at 32.96%), 7.44% from medical devices, and smaller percentages from other categories such as health foods and personal care products [2]. Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion yuan, a year-on-year decrease of 2.77%, and a net profit attributable to shareholders of 101 million yuan, down 0.22% year-on-year [2]. - The company has distributed a total of 715 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Jianzhijia had 15,100 shareholders, a slight decrease of 0.04% from the previous period, with an average of 10,240 circulating shares per shareholder, which increased by 0.04% [2]. - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund holds 7.1 million shares, unchanged from the previous period, while the Guangfa Innovation Upgrade Mixed Fund has exited the top ten list [3].

Group 1 - The core point of the article is that Jianzhijia (605266) announced that as of the date of the announcement, the company has no overdue external guarantees [1] Group 2 - The announcement was made on the evening of December 19 [1] - The company is in compliance with its financial obligations regarding external guarantees [1]

| 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 194,357.40 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 69.48 | | 特别风险提示 | 对外担保总额（含本次）超过上市公司最近一 | | | 期经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最近 | | | 一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达到 | | | 或超过最近一期经审计净资产 30% | | | □本次对资产负债率超过 70%的单位提供担保 | | 其他风险提示 | 无 | 证券代码：605266 证券简称：健之佳 公告编号：2025-057 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 广西健之佳勤康医药销售有限公司 | | --- ...

Core Viewpoint - The stock price of Jianzhijia has experienced a decline of 10.24% year-to-date, with a recent slight recovery in the last five trading days, indicating potential volatility in the market performance of the company [2]. Group 1: Stock Performance - As of December 19, Jianzhijia's stock price decreased by 2.03%, trading at 19.76 yuan per share, with a total market capitalization of 30.54 billion yuan [1]. - The stock has shown a 2.60% increase over the last five trading days and a 0.51% increase over the last 20 days, while it has declined by 8.18% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion yuan, reflecting a year-on-year decrease of 2.77%, and a net profit attributable to shareholders of 101 million yuan, down by 0.22% year-on-year [2]. - The company has distributed a total of 715 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [3]. Group 3: Business Overview - Jianzhijia, established on September 27, 2004, and listed on December 1, 2020, operates in the health product retail sector, offering a range of products including pharmaceuticals, health foods, personal care items, and daily consumables [2]. - The revenue composition of Jianzhijia includes 72.60% from prescription and non-prescription drugs, with non-prescription drugs accounting for 39.64% and prescription drugs for 32.96% [2]. - The company is categorized under the pharmaceutical and biological industry, specifically in the offline pharmacy segment, and is associated with concepts such as retail pharmacies and family doctor services [2].

（编辑 丛可心） 证券日报网讯 12月17日，健之佳在互动平台回答投资者提问时表示，公司以顾客需求为核心，聚焦主 业，长期专注于差异化定位的药品零售、便利零售行业，持续强化核心竞争力。面对政策影响、医药消 费低迷、行业短期压力和中期转型挑战，公司迅速调整短期经营策略，坚决转型，聚焦存量门店效率以 争取市场份额。非常感谢投资者对公司的关注以及提出的转型建议，一方面对跨行业、跨界进入不熟 悉、公司尚未具备优势的竞争性领域，公司持开放但审慎的态度评估风险及自身能力潜力，另一方面， 坚决推进转型工作，以提升店效、人效。 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-056 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 担 保 | 对 | 被担保人名称 本次担保金额 | 12,500 | 万元 | 云南健之佳连锁健康药房有限公司 | | --- | --- | --- | --- | --- | --- | | 象一 | | 实际为其提供的担保余额 | 62,859.45 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 本次担保金额 | 3,000 | 云南之佳便利店有限公司 万元 万元 | | | | | 实际为其提供的担保余额 | 3,814.99 | | | | 象二 | | | | | | | | | 是否在前期预计额度内 | ...

Core Viewpoint - The stock price of Jianzhijia has shown a slight increase of 2.04% on November 26, 2023, with a current price of 20.52 CNY per share, despite a year-to-date decline of 6.79% [1] Company Overview - Jianzhijia Pharmaceutical Chain Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on September 27, 2004. The company was listed on December 1, 2020. Its main business involves the retail of health products, including pharmaceuticals, health foods, personal care products, and daily consumables [1] - The revenue composition of Jianzhijia includes: prescription and non-prescription drugs (72.60%), with non-prescription drugs at 39.64% and prescription drugs at 32.96%. Other segments include medical devices (7.44%), other (5.52%), convenience products (5.05%), health foods (4.84%), traditional Chinese medicine (3.28%), personal care products (1.18%), and health check services (0.09%) [1] Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion CNY, a year-on-year decrease of 2.77%. The net profit attributable to the parent company was 101 million CNY, reflecting a slight decrease of 0.22% year-on-year [2] - Since its A-share listing, Jianzhijia has distributed a total of 715 million CNY in dividends, with 473 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Jianzhijia had 15,100 shareholders, a slight decrease of 0.04% from the previous period. The average circulating shares per person increased by 0.04% to 10,240 shares [2] - Among the top ten circulating shareholders, Rongtong Health Industry Flexible Allocation Mixed A/B holds 7.1 million shares, remaining unchanged from the previous period. Meanwhile, Guangfa Innovation Upgrade Mixed has exited the top ten list [3]

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

证券日报网讯健之佳（605266）11月19日在互动平台回答投资者提问时表示，公司在定期报告中披露公 司股东相关信息，敬请查阅。除定期报告要求外，公司未披露股东人数或持股情况，考虑到信息披露的 公平性原则，公司不宜向单个股东提供上述信息。 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.92% on November 18, with Yao Yigou leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Notable gainers included: - Ren Da Medical (603108) with a closing price of 15.97, up 2.90% and a trading volume of 278,200 shares, totaling 442 million yuan [1] - People's Tongtai (600829) with a closing price of 17.72, up 6.49% and a trading volume of 1,148,700 shares, totaling 1.902 billion yuan [1] - Major decliners included: - Yao Yigou (300937) with a closing price of 33.95, down 6.37% and a trading volume of 115,000 shares, totaling 396 million yuan [2] - Luhua Pharmaceutical (002788) with a closing price of 10.29, down 5.86% and a trading volume of 467,300 shares, totaling 489 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 706 million yuan from institutional investors, while retail investors contributed a net inflow of 705 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing while retail investors remained active [2] Individual Stock Capital Flow - Ren Da Medical (603108) had a net inflow of 49.2 million yuan from institutional investors, while retail investors saw a net outflow of 65.5 million yuan [3] - Yao Yigou (300937) experienced a significant net outflow of 560.4 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different stocks within the sector [3]